readthroughSign in
CompanyCLRBNasdaqFlorham Park, NJ

Cellectar Biosciences, Inc.

Cellectar Biosciences develops iopofosine I 131, a radiopharmaceutical using its Phospholipid Drug Conjugate platform for targeted cancer delivery.

SCHEDULE 13G/ANov 16Latest SEC filing
Nov 10Latest story